Q1 2024 Summary
Published Jan 31, 2025, 2:42 PM UTC- The company has achieved its highest ever EBITDA minus patient CapEx of $8 million or 12.3%, indicating improved profitability and operational efficiency, with continuous improvement over prior quarters.
- Strong demand in the sleep business is leading to increased compliance and higher utilization of CPAP and BiPAP devices among patients, especially those using GLP-1 medications, resulting in higher supply orders and supporting growth in this segment.
- The company is expanding its salesforce and entering new markets within the states it currently operates, indicating continued growth prospects and market penetration.
- The company is currently under investigation by the Department of Justice (DOJ) related to a Civil Investigative Demand (CID) concerning potential billing practices. Management acknowledged the inquiry but cannot estimate potential charges or timelines, creating uncertainty and potential legal risks for investors. , , , ,
- The ongoing DOJ investigation could potentially distract management and impact operational focus, including possible effects on mergers and acquisitions (M&A) strategies. While management stated that operations are not currently affected, prolonged legal inquiries might pose challenges. , ,
- The uncertainty regarding the outcome and duration of the DOJ investigation may negatively affect the company's stock valuation. Analysts noted that such cases often take years to resolve and can result in significant settlements or penalties, which could impact the company's financial position. , ,
-
DOJ Investigation Details
Q: Can you discuss the DOJ investigation?
A: The company is undergoing an ongoing inquiry from the Department of Justice, specifically a Civil Investigative Demand (CID), which is a request for information to gather facts necessary for regulatory authorities to determine if any violation has occurred. The government has not concluded any wrongdoing, and the company believes it has strong internal controls on billing and compliance procedures and remains confident in its practices. -
Cash Flow Sustainability
Q: Is the high EBITDA minus patient CapEx ratio sustainable?
A: The EBITDA minus patient CapEx ratio reached $8 million or 12.3%, the highest it has ever been. Management is pleased with the continuous improvement seen in recent quarters and, while encouraging investors to view it on a rolling 12-month basis to smooth out timing spikes, believes the positive trend is heading in the right direction. -
Resupply Program Contribution
Q: How much does the resupply program contribute to cash flow?
A: The resupply program, with 172,000 patients as of December 31, generates significant cash flow since it doesn't require associated CapEx. It accounts for approximately $106 million in annualized revenue, contributing higher net cash flow that exceeds that from medical equipment less CapEx. While it has its own variable costs, the resupply program is a notable contributor to improved cash flows. -
M&A Pipeline Outlook
Q: Can you provide an update on the M&A pipeline?
A: The company continues to selectively pursue deals, maintaining a disciplined approach to M&A. While deals are at various stages, there is a steady flow consistent with what was seen in 2022 and 2023. Management is not disclosing specific numbers but remains confident in ongoing M&A opportunities. -
GLP-1s and CPAP Strategy
Q: How are you addressing changes in CPAP utilization related to GLP-1s?
A: The company is internally discussing medium and long-term strategies to address potential changes in CPAP utilization due to GLP-1 medications. A recent study by a major sleep device manufacturer found that patients using GLP-1s were more likely to be compliant with their CPAP or BiPAP devices and ordered supplies more frequently. This suggests that as patients become more health-conscious, demand for sleep therapy may increase, and the company expects this trend to continue. -
E-Prescribing Adoption
Q: How will you increase e-prescribing adoption from under 5%?
A: The main challenge is physician adoption. The company is partnering with a company they partially own to start sending supplier-initiated orders, encouraging doctors to use the portal for prescription renewals. By demonstrating the ease of approving prescriptions with one click, they hope to increase e-prescribing adoption, which allows orders to be processed and delivered more efficiently, sometimes same day. -
Sales Force Expansion
Q: What's the update on sales force size and market expansion?
A: The company met its sales force expansion goal for '23 and has set a new goal for '24. They are onboarding additional sales reps, focusing on expanding services within states where they currently operate, such as moving further south in Florida. This expansion aims to capitalize on opportunities in existing markets. -
Medicare Advantage Impact
Q: Have you seen increased utilization of Medicare Advantage plans?
A: While monitoring patients transitioning from traditional Medicare to Medicare Advantage, the company hasn't observed any material differences from prior years. Certain regions show more conversions, but overall, there is no significant impact on the organization. -
Industry Investigations
Q: Have you seen similar DOJ investigations in the industry?
A: It is not uncommon for Durable Medical Equipment (DME) or healthcare companies in the U.S. to receive such inquiries, especially larger ones. Each case is unique, and the company emphasizes that the government has not concluded any wrongdoing. They remain confident in their internal controls and billing practices. -
DOJ Investigation Outcomes
Q: Can you frame potential outcomes of the DOJ investigation?
A: While public information often highlights cases resulting in settlements or negative outcomes, many investigations conclude without such results. The company is currently in the predetermination phase and does not believe there has been any wrongdoing. They cannot estimate potential charges or timelines, as cases can take different paths and durations. They will continue to provide updates, ensuring transparency, and remain focused on their strategic plan without operational impact from the investigation.